US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)

0.1750

0.0000

Volume:131.00

Turnover:20.73

Market Cap:307.14K

PE:- -

High:0.1750

Open:0.1750

Low:0.1750

Close:0.1750

52wk High:1.52

52wk Low:0.1200

Shares:1.76M

Float Shares:1.76M

Volume Ratio:0.01

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

BRIEF-Briacell Therapeutics Announces Pricing Of $30 Million Public Offering At $5.59 Per Unit

Briacell Therapeutics Corp - Units Sold at $5.59 per Unit for $30 Mln Gross Proceeds

THOMSON REUTERS

Briacell Therapeutics Announces Pricing of $30 Million Public Offering

THOMSON REUTERS

BRIEF-Briacell Phase 3 Trial Featured In Nature Medicine

“Eleven Clinical Trials That Will Shape Medicine in 2026” – Briacell Phase 3 Trial Featured in Nature Medicine

THOMSON REUTERS

BRIEF-BriaCell's Phase 3 Patient Enrollment On Track For 1H2026 Topline Data Readout

Briacell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

THOMSON REUTERS

Briacell Therapeutics Corp - Topline Interim Data Readout Expected in 1H2026

THOMSON REUTERS

BRIEF-Briacell And Receptor.Ai To Collaborate On Ai Driven Small Molecule Cancer Therapeutics

Briacell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

THOMSON REUTERS

BRIEF-BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Briacell Therapeutics Corp - Phase 3 Study Under FDA Fast Track Designation Being Conducted

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCTXZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCTXZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXZ\",,,,,undefined,":{"symbol":"BCTXZ","market":"US","secType":"STK","nameCN":"BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM)","latestPrice":0.175,"timestamp":1770670800000,"preClose":0.175,"halted":0,"volume":131,"delay":0,"changeRate":0,"floatShares":1755109,"shares":1755109,"eps":0,"marketStatus":"Post-Mkt","change":0,"latestTime":"02-09 17:20:12 EST","open":0.175,"high":0.175,"low":0.175,"amount":20.729198,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770685200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.175,"volumeRatio":0.007592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXZ\",,,,,undefined,":{"symbol":"BCTXZ","floatShares":1755109,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.007592,"shares":1755109,"dividePrice":0,"high":0.175,"amplitude":0,"preClose":0.175,"low":0.175,"week52Low":0.12,"pbRate":"--","week52High":1.515,"institutionHeld":0,"latestPrice":0.175,"eps":0,"divideRate":0,"volume":131,"delay":0,"ttmEps":0,"open":0.175,"prevYearClose":0.2902,"prevWeekClose":0.175,"prevMonthClose":0.1902,"prevQuarterClose":0.2902,"fiveDayClose":0.1949,"twentyDayClose":0.27,"sixtyDayClose":0.345},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCTXZ\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCTXZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCTXZ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCTXZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603657112","title":"BRIEF-Briacell Therapeutics Announces Pricing Of $30 Million Public Offering At $5.59 Per Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2603657112","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603657112?lang=en_us&edition=fundamental","pubTime":"2026-01-14 10:01","pubTimestamp":1768356113,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell Therapeutics Announces Pricing Of $30 Million Public Offering At $5.59 Per Unit Jan 13 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL THERAPEUTICS ANNOUNCES PRICING OF $30 MILLI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUAB4VXHV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXW","BCTXZ"],"gpt_icon":0},{"id":"2603901657","title":"Briacell Therapeutics Corp - Units Sold at $5.59 per Unit for $30 Mln Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2603901657","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603901657?lang=en_us&edition=fundamental","pubTime":"2026-01-14 10:00","pubTimestamp":1768356023,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUAB4VXHV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXZ","BCTXW"],"gpt_icon":0},{"id":"2603657909","title":"Briacell Therapeutics Announces Pricing of $30 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2603657909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603657909?lang=en_us&edition=fundamental","pubTime":"2026-01-14 10:00","pubTimestamp":1768356023,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nTUAB4VXHV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW","BCTXZ"],"gpt_icon":0},{"id":"2592905905","title":"BRIEF-Briacell Phase 3 Trial Featured In Nature Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2592905905","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592905905?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:45","pubTimestamp":1766061925,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell Phase 3 Trial Featured In Nature MedicineDec 18 (Reuters) - Briacell Therapeutics Corp BCT.TO:“ELEVEN CLINICAL TRIALS THAT WILL SHAPE MEDICINE IN 2026” – BRIACELL PHASE 3 TRIAL FEATURED","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA9SMH7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXZ","BCTXW"],"gpt_icon":0},{"id":"2592037429","title":"“Eleven Clinical Trials That Will Shape Medicine in 2026” – Briacell Phase 3 Trial Featured in Nature Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2592037429","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592037429?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA9SMH7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW","BCTXZ"],"gpt_icon":0},{"id":"2590345086","title":"BRIEF-BriaCell's Phase 3 Patient Enrollment On Track For 1H2026 Topline Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2590345086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590345086?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:31","pubTimestamp":1765283502,"startTime":"0","endTime":"0","summary":"BRIEF-BriaCell's Phase 3 Patient Enrollment On Track For 1H2026 Topline Data ReadoutDec 9 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL’S PHASE 3 PATIENT ENROLLMENT ON TRACK FOR 1H2026 TOPLIN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA4PPH80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXW","BCTXZ"],"gpt_icon":0},{"id":"2590754345","title":"Briacell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2590754345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590754345?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:30","pubTimestamp":1765283401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA4PPH80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXZ","BCTXW"],"gpt_icon":0},{"id":"2590345756","title":"Briacell Therapeutics Corp - Topline Interim Data Readout Expected in 1H2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590345756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590345756?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:30","pubTimestamp":1765283401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA4PPH80:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXZ","BCTXW"],"gpt_icon":0},{"id":"2584346321","title":"BRIEF-Briacell And Receptor.Ai To Collaborate On Ai Driven Small Molecule Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2584346321","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584346321?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:14","pubTimestamp":1763644487,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell And Receptor.Ai To Collaborate On Ai Driven Small Molecule Cancer TherapeuticsBriacell Therapeutics Corp BCT.TO:BRIACELL AND RECEPTOR.AI TO COLLABORATE ON AI DRIVEN SMALL MOLECULE CANCER THERAPEUTICSSource text: ID:nGNX5VthjSFurther company coverage: BCT.TO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA4VGJZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXZ","BCTXW"],"gpt_icon":0},{"id":"2584130139","title":"Briacell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2584130139","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584130139?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:30","pubTimestamp":1763641800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA4VGJZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXZ","BCTXW"],"gpt_icon":0},{"id":"2577836642","title":"BRIEF-BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2577836642","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577836642?lang=en_us&edition=fundamental","pubTime":"2025-10-22 19:37","pubTimestamp":1761133076,"startTime":"0","endTime":"0","summary":"BRIEF-BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast CancerOct 22 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL RECE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W31XZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXZ","BCTXW"],"gpt_icon":0},{"id":"2577366955","title":"Briacell Therapeutics Corp - Phase 3 Study Under FDA Fast Track Designation Being Conducted","url":"https://stock-news.laohu8.com/highlight/detail?id=2577366955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577366955?lang=en_us&edition=fundamental","pubTime":"2025-10-22 19:30","pubTimestamp":1761132651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W31XZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXZ","BCTXW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}